Phathom Pharmaceuticals Inc (PHAT)
6.95
-0.25
(-3.47%)
USD |
NASDAQ |
Jan 08, 16:00
6.945
0.00 (0.00%)
After-Hours: 20:00
Phathom Pharmaceuticals SG&A Expense (Quarterly): 76.10M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Merck & Co Inc | 2.731B |
| Galectin Therapeutics Inc | 1.471M |
| AbbVie Inc | 4.205B |
| Poseida Therapeutics Inc | 10.09M |
| Janux Therapeutics Inc | 17.67M |